Latest news with #ADPT
Yahoo
4 days ago
- Business
- Yahoo
Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2025 after market close on Tuesday, August 5, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the 'Investors' section of the company website at: The webcast will be archived and available for replay within 24 hours after the event. About Adaptive Biotechnologies Adaptive Biotechnologies ('we' or 'our') is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. ADAPTIVE INVESTORSKarina Calzadilla, Vice President, Investor Relations and FP&A201-396-1687investors@ ADAPTIVE MEDIAErica Jones, Associate Corporate Communications Director206-279-2423media@
Yahoo
25-06-2025
- Business
- Yahoo
Craig-Hallum Initiates Coverage of Adaptive Biotechnologies (ADPT) stock, Gives Buy
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers. On June 18, Craig-Hallum began coverage of Adaptive Biotechnologies Corporation (NASDAQ:ADPT)'s stock with a 'Buy' rating and a price objective of $15, as reported by The Fly. A doctor presenting a new diagnostic test to a patient in an exam room. The research firm believes that the company is an unequivocal leader in testing to measure minimal residual disease (MRD) in patients with hematologic malignancies. The firm opines that Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is essentially the only player in the $1.8 billion heme MRD market, which has potential for sustainable 20%+ growth, and several near-term growth drivers. It also has the potential to turn EBITDA break-even in core business, a track record of exceeding the estimates, and an expectation for robust margin expansion. The firm highlighted that clonoSEQ test is capable of detecting very small quantities of cancer cells, which may remain during or after treatment. As per the research note, the ability of the test to monitor MRD status supports physicians in determining treatment efficacy and making therapy adjustments as required. The firm also highlighted that MRD testing can identify cancer recurrence earlier than alternative diagnostic methods, offering an advantage for patient care. Craig-Hallum mentioned certain near-term catalysts for Adaptive Biotechnologies Corporation (NASDAQ:ADPT), such as increased coverage and payor reimbursement rates, EMR integrations, adoption of MRD in clinical trials, and a strategic partnership with NeoGenomics (NEO). Furthermore, a transition to a new test platform is expected to fuel gross margins. Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is a commercial-stage biotechnology company that is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. While we acknowledge the potential of ADPT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ADPT and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-06-2025
- Business
- Yahoo
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adaptive Biotechnologies (ADPT) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Adaptive Biotechnologies is a member of the Medical sector. This group includes 998 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Adaptive Biotechnologies is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for ADPT's full-year earnings has moved 5.5% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend. Based on the latest available data, ADPT has gained about 74.5% so far this year. At the same time, Medical stocks have lost an average of 2.3%. This shows that Adaptive Biotechnologies is outperforming its peers so far this year. Another stock in the Medical sector, CVS Health (CVS), has outperformed the sector so far this year. The stock's year-to-date return is 43.2%. In CVS Health's case, the consensus EPS estimate for the current year increased 4.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Breaking things down more, Adaptive Biotechnologies is a member of the Medical - Biomedical and Genetics industry, which includes 502 individual companies and currently sits at #80 in the Zacks Industry Rank. On average, this group has lost an average of 0.2% so far this year, meaning that ADPT is performing better in terms of year-to-date returns. CVS Health, however, belongs to the Medical Services industry. Currently, this 58-stock industry is ranked #69. The industry has moved -0.9% so far this year. Investors with an interest in Medical stocks should continue to track Adaptive Biotechnologies and CVS Health. These stocks will be looking to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Adaptive Biotechnologies Corporation (ADPT) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
